the Efficacy and Safety of Curcuma Longa Extract Mixture on Immune Enhancement

Study Overview
=================
Brief Summary
-----------------
This study was conducted to investigate the efficacy and safety of Curcuma longa extract mixture on immune enhancement

Detailed Description
-----------------
This study was 8 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Curcuma longa extract mixture on immune enhancement

Official Title
-----------------
This Study Was a 8 Weeks, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Curcuma Longa Extract Mixture on Immune Enhancement

Conditions
-----------------
Immunity

Intervention / Treatment
-----------------
* Dietary Supplement: Curcuma Longa Extract Mixture
* Dietary Supplement: placebo group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult men and women over 19 and under 75 years After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice Exclusion Criteria: If screening shows that the white blood cell(WBC) is less than 3000/㎕ or more than 8000/㎕ Those who received influenza vaccination within 2 months before first intake of intervention Those who have a body mass index(BMI) of less than 18.5 kg / m^2 or greater than 35 kg / m^2 at the screening Those who have a clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, liver biliary system, kidney and urinary system, neuropsychiatry, musculoskeletal system, inflammatory and hematologic and gastrointestinal disorders Those who take a medication or health function food that affects your promotion of immunity within 1 month prior to the screening Those who have received antipsychotic medication within 3 months before screening Those who alcoholic or drug abuse suspected Those who participated in other clinical trials within 3 months before screening Laboratory test by show the following results Aspartate Transaminase(AST), Alanine Transaminase(ALT) > Reference range 3 times upper limit Serum Creatinine > 2.0 mg/dL Pregnancy or breast feeding Those who doesn't accept the implementation of appropriate contraception of a childbearing woman Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Curcuma longa L. extract mixture group<br>2 times a day, 2 capsule for 1 time, after breakfast and dinner meal (1.6 g/day, Curcuma longa L. extract mixture 1 g/day) | Dietary Supplement: Curcuma Longa Extract Mixture<br>* 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week<br>|
| Placebo Comparator: placebo group<br>2 times a day, 2 capsule for 1 time, after breakfast and dinner meal (1.6 g/day, Curcuma longa L. extract mixture 0 g/day) | Dietary Supplement: placebo group<br>* 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes of Natural Killer cell activity | Natural Killer cell activity was measured in study baseline and 8 week, using A ratio of effector cell to target cell ratio of 2.5:1, 5:1, 10:1. Natural Killer cell activity(%) = (Experimental - Effector Spontaneous - Target Spontaneous) / (Target Maximum - Target Spontaneous) × 100 | baseline and 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes of Interleukin-2, Interleukin-12, Interferon-Gamma and Tumor necrosis factor-alpha | For blood Interleukin-2(pg/mL), Interleukin-12(pg/mL), Interferon-Gamma(pg/mL) and Tumor necrosis factor-alpha(pg/mL) analysis, collect 3 ml of blood in one serum separate tube for 5 ml, leave at room temperature for 30 minutes for clotting, after then centrifuge at 3000 rpm (or 2000 xg) for 10 minutes. | baseline and 8 weeks | 
| Changes of Wisconsin Upper Respiratory Symptom Survey-21(WURSS-21) | The Wisconsin Upper Respiratory Symptom Survey-21 will investigate on the day of visit (1st, 2nd and 3rd visits). The Wisconsin Upper Respiratory Symptom Survey-21 consists of seven stages, including individual symptoms, functional quality of life, and overall improvement. Find the total score of symptoms by obtaining the sum of symptom questions, and the total score of quality of life by obtaining the sum of life questions. Additionally, the sum of the total points of symptoms and quality of life is obtained. All items of symptom score rank on a seven-point scale(1=very mild and 7=severe), where a higher score means higher severity. The symptom score ranges from 0(Do not have this symptom) to 70. All items of quality of life score rank on a seven-point scale(1=very mildly and 7=severely), where a higher score means higher severity. The quality of life score ranges from 0(Not at all) to 63. Therefore, the total score ranges from 0 to 133. | baseline, 4 weeks and 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immunity, Curcuma Longa